Author Archives: oskar.hansson@med.lu.se

Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Hansson O et al. Alzheimer’s Research & Therapy. 2014;6(3):25. INTRODUCTION: The objective was to study whether alpha-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls. METHODS: In total, 247 CSF samples were assessed […]

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies

Nielsen HM et al. Journal of Alzheimer’s Disease. 2014;40(2):343-50 The proteoglycan NG2 plays a major role in proliferation, migration, and differentiation of pericytes and NG2 cells in the brain. We have previously reported decreased soluble NG2 (sNG2) levels in cerebrospinal fluid (CSF) from patients with Alzheimer’s disease (AD) and a relationship between sNG2 and AD […]

Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment

Lindqvist D et al. Brain, Behavior, and Immunity. 2013;33:183-9 Neuroinflammation may be involved in the pathophysiology of Parkinson’s disease (PD) and specifically in non-motor symptoms such as depression, fatigue and cognitive impairment. The aim of this study was to measure inflammatory markers in cerebrospinal fluid (CSF) samples from PD patients and a reference group, and to […]

Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography

Surova Y et al. PloS One. 2013;8(6):e66022. PURPOSE: The aim of the study was to determine the usefulness of diffusion tensor tractography (DTT) in parkinsonian disorders using a recently developed method for normalization of diffusion data and tract size along white matter tracts. Furthermore, the use of DTT in selected white matter tracts for differential diagnosis was […]

Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy

Wennström M, et al. PloS one. 2013;8(1):e53250 Neurosin is a protease that in vitro degrades alpha-synuclein, the main constituent of Lewy bodies found in brains of patients with synucleinopathy including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Several studies have reported reduced cerebrospinal fluid (CSF) levels of alpha-synuclein in synucleinopathy patients and recent data […]

Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseases

Nutu M et al. Neuromolecular Medicine. 2013;15(1):169-79. Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) reflect brain biochemistry. Using combined immunoprecipitation and mass spectrometry, we have shown that amyloid beta 1-15 (Abeta1-15) is produced by concerted beta- and alpha-secretase cleavage of amyloid precursor protein (APP) and that the relative levels of Abeta1-16 in AD compared to […]